BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an alternative to conventional surgery in high-risk patients with severe aortic stenosis (AS), but data regarding mitral regurgitation (MR) characteristics and changes after TAVI are sparse. METHODS: A total of 254 patients with severe AS referred for TAVI were prospectively enrolled. Comprehensive echocardiography was performed at baseline and at 7 days and 1 month in patients who underwent TAVI. MR was semiquantitatively graded from 0 to 4. Overlap of the anterior mitral leaflet and the device was measured using transesophageal echocardiography immediately after TAVI. RESULTS: At screening, MR was absent in 26%, grade 1 in 44%, grade 2 in 25%, and grade ≥3 in 5% and was organic in 68% and functional in 32%. TAVI was finally performed using the Edwards Sapien valve in 119 patients, including four with MR grade ≥ 3. MR grade significantly decreased at 7 days (P = .003) but remained unchanged at 1 month (P = .55), whereas reverse remodeling occurred only at 1 month (improvements in left ventricular [LV] end-systolic diameter and ejection fraction; P < .05 for both). MR changes over time significantly differed according to ejection fraction and LV diameters (all P values for interaction < .005) but not according to aortic mean gradient, MR etiology, or overlap of the anterior mitral leaflet and the device (all P values for interaction > .15). CONCLUSIONS: In patients referred for TAVI, MR is common, mainly organic, and rarely severe. After TAVI, MR improved within 7 days in both organic and functional MR, was not influenced by overlap of the anterior mitral leaflet and the device, but was associated with improvement in LV ejection fraction. Possible MR improvement should be taken into account in patient selection for TAVI especially, in cases of LV dysfunction or enlargement and MR of borderline severity.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an alternative to conventional surgery in high-risk patients with severe aortic stenosis (AS), but data regarding mitral regurgitation (MR) characteristics and changes after TAVI are sparse. METHODS: A total of 254 patients with severe AS referred for TAVI were prospectively enrolled. Comprehensive echocardiography was performed at baseline and at 7 days and 1 month in patients who underwent TAVI. MR was semiquantitatively graded from 0 to 4. Overlap of the anterior mitral leaflet and the device was measured using transesophageal echocardiography immediately after TAVI. RESULTS: At screening, MR was absent in 26%, grade 1 in 44%, grade 2 in 25%, and grade ≥3 in 5% and was organic in 68% and functional in 32%. TAVI was finally performed using the Edwards Sapien valve in 119 patients, including four with MR grade ≥ 3. MR grade significantly decreased at 7 days (P = .003) but remained unchanged at 1 month (P = .55), whereas reverse remodeling occurred only at 1 month (improvements in left ventricular [LV] end-systolic diameter and ejection fraction; P < .05 for both). MR changes over time significantly differed according to ejection fraction and LV diameters (all P values for interaction < .005) but not according to aortic mean gradient, MR etiology, or overlap of the anterior mitral leaflet and the device (all P values for interaction > .15). CONCLUSIONS: In patients referred for TAVI, MR is common, mainly organic, and rarely severe. After TAVI, MR improved within 7 days in both organic and functional MR, was not influenced by overlap of the anterior mitral leaflet and the device, but was associated with improvement in LV ejection fraction. Possible MR improvement should be taken into account in patient selection for TAVI especially, in cases of LV dysfunction or enlargement and MR of borderline severity.
Authors: Asife Sahinarslan; Francesco Vecchio; Philip MacCarthy; Rafal Dworakowski; Ranjit Deshpande; Olaf Wendler; Mark Monaghan Journal: Acta Cardiol Sin Date: 2016-07 Impact factor: 2.672
Authors: R Jansen; A M Wind; M J Cramer; F Nijhoff; P Agostoni; F Z Ramjankhan; W J Suyker; P R Stella; S A J Chamuleau Journal: Int J Cardiovasc Imaging Date: 2018-03-10 Impact factor: 2.357
Authors: Ali Almasood; Saeed Al Ahmari; Haytham El-Shurafa; Mohammed Alotaibi; Saad Al Kasab; Moheeb AlAbdallah; Abdulrahman Al-Moghairi; Abdullah Al Khushail; Husain Al-Amri Journal: J Saudi Heart Assoc Date: 2014-05-26
Authors: Mathieu Vergnat; Melissa M Levack; Benjamin M Jackson; Joseph E Bavaria; Howard C Herrmann; Albert T Cheung; Stuart J Weiss; Joseph H Gorman; Robert C Gorman Journal: Ann Thorac Surg Date: 2012-12-13 Impact factor: 4.330
Authors: M Z Khawaja; R Williams; J Hung; S Arri; K N Asrress; K Bolter; K Wilson; C P Young; V Bapat; J Hancock; M Thomas; S Redwood Journal: Heart Date: 2014-08-25 Impact factor: 5.994
Authors: Piotr Szymański; Tomasz Hryniewiecki; Maciej Dąbrowski; Danuta Sorysz; Janusz Kochman; Jan Jastrzębski; Tomasz Kukulski; Marian Zembala Journal: Heart Date: 2016-02-23 Impact factor: 5.994
Authors: Luciana de Cerjat Bernardes P da Cunha; Enio Eduardo Guerios; Claudio Leinig Pereira da Cunha; Luiz A Carvalho; Pedro Lemos Neto; Rogério Sarmento-Leite; Alexandre A Abizaid; José Antonio Mangione; Adriano Dourado Oliveira; Alexandre Siciliano; Vinicius Esteves; Fábio Sândoli de Brito Journal: Arq Bras Cardiol Date: 2021-06 Impact factor: 2.000